| Industry > |
Blood/Biotechnology Industry Resource Center
FDA's Biologics Industry Portal
About the FDA Center for Biologics Evaluation and Research
FDA's Center for Biologics Evaluation and Research regulates
the following products: allergenic extracts, monoclonal antibodies,
biotech derived therapeutics, somatic cell and gene therapy, xenotransplantation,
tissues, some devices, whole blood, blood components, blood derivatives, and
vaccines.
CBER's Frequently Asked Questions
CBER Manufacturers' Assistance Site
Commemorating 100 Years of Biologics Regulation
Action Plans
 | Blood |
| Device |
| Tissue |
| Xenotransplantation |
CBER's Industry Assistance Information
Center For Biologics Evaluation and Research Web Site
Contact CBER at cber_info@cber.fda.gov or octma@cber.fda.gov .
Issues Concerning Blood and Biotechnology
A New Kind of Fish Story: The Coming of Biotech Animals
Testimony of Jesse Goodman, M.D., MPH, Director, Deputy Director of the Center for Biologics Evaluation and Research, to discuss FDA's response to the emerging threat of transmission of West Nile virus (WNV) through blood and tissue. (September 24, 2002)
![[ Yahoo! News Search ]](http://us.yimg.com/i/yahootogo/ytg_news.gif){kind=small}
for News in the Biotechnology Industry
)
retain their original
formatting, and require the free Adobe Acrobat Reader to view. This
product can be downloaded at no charge from 
